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Abstract
The advent of sensitive genetic testing modalities for the diagnosis of Prader-Willi syndrome has helped to define
not only the phenotypic features of the syndrome associated with the various genotypes but also to anticipate
clinical and psychological problems that occur at each stage during the life span. With advances in hormone
replacement therapy, particularly growth hormone children born in circumstances where therapy is available are
expected to have an improved quality of life as compared to those born prior to growth hormone.
This manuscript was prepared as a primer for clinicians-to serve as a resource for those of you who care for
children and adults with Prader-Willi syndrome on a daily basis in your practices. Appropriate and anticipatory
interventions can make a difference.
Introduction
First described by Prader, Labhart and Willi in 1956 [1],
this syndrome represents the most common genetic
cause of obesity with an estimated incidence of 1:15,000
to 1:25,000 live births [2,3]. Reported prevalence rates
vary among countries but both sexes appear to be
equally affected. Prader-Willi syndrome (PWS) is the
first human syndrome identified with genomic imprint-
ing [4]. The original descriptions of this syndrome
included short stature, hypotonia, hypogonadism and
mental retardation [1]. As infants grow to age 2-4 years,
failure to thrive related, at least in part, to poor muscle
tone and poor suck are replaced by increased appetite
and food intake resulting in obesity and its comorbid-
ities. Early diagnosis and intervention to prevent obesity
and the associated complications are critical.
Genetic testing and genetic counseling
Candidate genes for Prader-Willi syndrome have been
located on the long arm of chromosome 15q11-q13.
These genes are physiologically imprinted and silenced
on the maternally inherited chromosome. PWS arises
when the paternally derived genes are missing, defective
or silenced. The frequencies of each are shown in Table
1.
High resolution chromosomal analysis (HRCA) is
done along with the fluorescence in situ hybridization
(FISH) to detect deletions and translocation of chromo-
some 15 [5]. Deletion has been divided in type I (TI)
and II (TII) according to the size. Studies indicate that
individuals with the TI (~500 kb larger than TII) gener-
ally have more behavioral and psychological problems
than individuals with the TII and UPD [6]. Negative
FISH or karyotype analysis does not exclude the diagno-
sis and thus if done first should be followed by DNA
methylation analysis. DNA methylation analysis is the
only technique which can both confirm and reject the
diagnosis of PWS, and therefore should typically be the
investigation of choice. This is most commonly done
using DNA methylation-specific techniques at the
SNURF-SNRPN locus [7,8]. If DNA methylation analy-
sis shows only a maternal pattern, then PWS is con-
firmed. Further methods may then be performed to
determine the genetic subtype and allow appropriate
genetic counseling. DNA methylation analysis has a sen-
sitivity exceeding 99%; however, it does not differentiate
between deletion, UPD and imprinting defect. In order
to distinguish a maternal UPD from an imprinting
defect, further DNA polymorphism analysis should be
performed on the proband and parents [9,10].
Most cases of Prader-Willi syndrome occur sporadi-
cally. The overall recurrence risk is dependent on the
type of molecular defect. In families where the proband
has either maternal disomy or deletion, the recurrence
risk is small (less than 1%). Patients with an imprinting
defect warrant further investigation in a specialized
laboratory to determine whether an imprinting center
deletion is present. Those families with a child with an
* Correspondence: mcataletto@winthrop.org
1The Prader-Willi Syndrome Center at Winthrop University Hospital, 120
Mineola Blvd.-Suite 210, Mineola, N.Y. 11501, USA
Full list of author information is available at the end of the article
Cataletto et al. International Journal of Pediatric Endocrinology 2011, 2011:12
http://www.ijpeonline.com/content/2011/1/12
© 2011 Cataletto et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.imprinting center deletion have a recurrence risk of up
to 50% if the father of the child is a carrier for the
imprinting center deletion [11]. When a deletion is the
result of a translocation or structural rearrangement
involving chromosome 15, then the recurrence risk can
be high. The actual risk in individual families depends
upon the rearrangement which they carry. Overall, the
risk of recurrence in the case of chromosomal transloca-
tions has been estimated up to 15%.
In the future the methylation-specific multiplex liga-
tion PCR amplification may be more widely used
because it has the advantage of combining dosing and
DNA methylation analysis in one assay, thus distinguish-
ing different subtypes [12].
Clinical Presentation
Infants with Prader-Willi syndrome present with neona-
tal hypotonia, hypoplasia of the clitoris/labia minora in
girls and small penis and undescended testis in boys.
Their hypotonia is associated with poor suck and feed-
ing, often resulting in failure to thrive. Mothers may
report decreased fetal activity and infants are often
found in the breech position at the time of delivery.
Clinical features include increased neonatal head:chest
circumference ratio, narrow bifrontal diameter, dolicho-
cephaly, almond shaped eyes, downturned angles of the
mouth with abundant and thick saliva, small hands and
feet with straight borders of the ulnar side of the hands
and inner side of the legs. The presence of some of
these features associated with neonatal hypotonia should
alert physicians for early diagnosis of PWS during
infancy. These features may become more prominent by
age 2-3 years (Figures 1 and 2). Excessive eating and
obsession with food generally begins in the preschool
age group and will lead to morbid obesity if not
controlled.
As these individuals age, manifestations, such as obe-
sity, short stature, hypogonadism, skin picking, learning
disabilities, behavioral and psychiatric problems become
more evident. Consensus criteria for the clinical diagno-
sis of PWS were first established in 1993 by Holm et al
[13]. These criteria were used until the introduction of
the highly sensitive genetic testing, described above.
Currently, these criteria are used as a screening tool for
determining the need for further PWS specific genetic
testing. In many infants poor cry and unexplained hypo-
tonia may be the only clear clinical manifestations and
indication for genetic testing.
As many as 16.7% of patients diagnosed with molecu-
lar testing do not meet these clinical diagnostic criteria,
therefore a revised clinical criteria to help identify the
appropriate patients for DNA testing was proposed in
2001 [14] and modified in 2008 [15]. See Table 2 for
composite, including additional features suggested by
authors.
Table 1 Frequency of genetic subtypes associated with
PWS
Subtype Frequency
Paternal deletion of chromosome 15q11-q13 (type I or II) 75%
Maternal uniparental disomy (UPD) 24%
Imprinting center defects (ID) 1%
Translocation < 1%
 
Figure 1 Typical Facial Features of Child with Prader-Willi
syndrome (Photograph with Permission).
Figure 2 Typical Findings of Hands and Legs in Individuals
with Prader-Willi syndrome.
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Hypogonadism
Hypothalamic and pituitary dysfunction is most com-
monly manifested as hypogonadism, obesity and short
stature. Hypogonadism with genital hypoplasia (cryp-
torchidism, scrotal or clitoral hypoplasia) can be identi-
fied in the newborn period. Cryptorchidism is present
up to 86% of boys from birth [16,17] Undescended
testes should be treated within the first year of life.
There is evidence that early damage to the germ cells
that produce sperm begins at this age. Scrotal hypopla-
sia and small penis however can make orchiopexy and
circumcision difficult in infants with PWS. Repeat surgi-
cal interventions are frequently required, especially in
those infants with underdeveloped scrotal sacs.
The most effective treatment for undescended testes is
surgery. The Committee on Genetics, American Acad-
emy of Pediatrics however, recommends a therapeutic
trial of human chorionic gonadotropin (hCG) for treat-
ment of undescended testes before surgery, because
avoidance of general anesthesia is desirable for infants
w i t hl o wm u s c l et o n ea n dp o t e n t i a lf o ru n d e r l y i n g
respiratory compromise [18]. The precise mechanism of
action in regards to testicular descent is unknown but
benefits of a course of hCG may include increased scro-
tal size and partial normalization of phallus length,
thereby improving surgical outcomes for undescended
testes and facilitating later standing micturition.
Premature adrenarche (PA) is the precocious appear-
ance of pubic and/or axillary hair and less commonly an
apocrine odor, comedones, and acne without other signs
of puberty or virilization. PA is usually seen before age
8 and 9 years, in girls and boys respectively. PA has
been reported in 57% of children receiving GH therapy
[19] but in general, pubertal development in PWS is
characterized by normal adrenarche, pubertal arrest, and
hypogonadism due to variable combinations of a unique
primary gonadal defect and hypothalamic dysfunction
[20,21].
At some stage almost all subjects will require sex hor-
mone replacement therapy. Mental retardation should
not be a contraindication to allow normal pubertal
development or preclude sex hormone replacement at
any age in those affected individuals. Regardless of body
weight, patients with PWS have increased body fat con-
tent. Those individuals with low body weight or signifi-
cant low sex hormone levels during adolescence and
adulthood should be considered for sex hormone treat-
ment. There is no consensus as to the most appropriate
regimen for sex hormone replacement therapy in PWS.
Intramuscular testosterone is given every 3 -4 weeks.
Testosterone gel preparations can be useful in selected
cases, although precautions must be taken to avoid
cross-contamination. Whatever preparation is preferred,
the initial dose should be one third to one half of the
normally recommended androgen dose to prevent the
aggressive behavior occasionally seen in some indivi-
duals. In females with PWS, the use of gonadal hormone
replacement should be considered if there is amenor-
rhea/oligomenorrhea or decreased bone mineral density
(BMD) in the presence of reduced estradiol levels.
Hypogonadism is a common but not necessarily univer-
sal finding in adults with PWS[ 1 6 , 1 7 ] .S e x u a lc o u n s e l -
ing and contraceptive treatment should be used as
appropriate, especially in the presence of complete sex-
ual maturation, including regular menses. There are a
few case reports of pregnancy in females with PWS
[22,23]. Their cognitive dysfunction, social and emo-
tional immaturity and the risk of Angelman syndrome
in offspring of PWS deletion mothers prompt us to
advise against pregnancy. At present there are no
reports of paternity in PWS. Estrogen and androgen
Table 2 Indications for DNA testing
Age at assessment Features sufficient to prompt DNA testing
Birth to 2 yr Hypotonia with poor suck
2-6 yr Hypotonia with a history of poor suck
Global developmental delay
Short stature and/or growth failure associated with accelerated weight gain
6-12 yr Hypotonia with a history of poor suck (hypotonia often persists)
Global developmental delay
Excessive eating (hyperphagia, obsession with food) with central obesity if uncontrolled
Short stature and/or decreased growth velocity*
13 yr through
adulthood
Cognitive impairment, usually mild mental retardation
Excessive eating (hyperphagia, obsession with food) with central obesity if uncontrolled
Short stature and/or decreased growth velocity*
Hypothalamic hypogonadism and/or typical behavior problems (including temper tantrums and obsessive-compulsive
features)
*Features added by the authors
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and adulthood and BMD assessed as indicated by dual-
energy x-ray photon absorptiometry.
Adrenal insufficiency
When the pituitary begins to fail, there is generally a
specific sequential failure of pituitary hormones, starting
with growth hormone (GH), continuing through lutei-
nizing (LH) and follicle stimulating hormone (FSH) defi-
ciency, and culminating in the loss of thyrotropin
stimulating hormone (TSH) and adrenocorticotropic
hormone (ACTH). Generally ACTH is the last to be
affected. Hypothalamic dysfunction is characteristic of
individuals with PWS, therefore the clinical manifesta-
tions of pituitary hormone deficiency are expected.
Short stature and hypogonadism, as a result of GH and
gonadotropin (LH and FSH) deficiencies are seen in
most individuals with this genetic syndrome. Under nor-
mal conditions the secretion of cortisol, the main adre-
nal glucocorticoid in humans is under the dominant
control of pituitary ACTH. Clinical manifestations of
adrenal insufficiency, however are uncommon in indivi-
duals with PWS.
The circadian peak serum cortisol usually occurs
around 0800 hours. An extremely low basal serum corti-
sol at this time, below 100 nmol/liter (3.62 mcg/dl), may
be assumed to demonstrate true cortisol deficiency [24].
However, levels at other times have little diagnostic uti-
lity. For this reason, various dynamic tests including
insulin tolerance test (ITT), ACTH stimulation and
metyrapone test have been devised to assess whether
the patient can provide a stress-induced rise in cortisol
similar to a normal person. The insulin tolerance test
evaluates the integrity of the entire hypothalamic-pitui-
tary axis (HPA) by inducing symptomatic and biochem-
ical hypoglycemia, with cortisol then measured over 120
minutes. Peak cortisol values greater than 550 nmol/liter
(19.75 mcg/dl) is considered a normal response. Under
supervision by a nurse or physician, the ITT (0.15 U/kg
administered intravenously (IV) is relatively safe [24].
The GH reserve can also be estimated with ITT.
Due to the relative inconvenience of the ITT, sugges-
tions have been made to use a simpler and less invasive
surrogate. The most widely performed is the short
ACTH (Cortrosyn ™) stimulation test, where ACTH
0.25 mg is injected IV or IM and serum cortisol is mea-
sure at 0, 30 and 60 minutes. A peak cortisol is defined
as normal if it is greater than 550 nmol/liter (19.75
mcg/dl) at any of these time points.
In 2008 a study using the overnight metyrapone test
reported a 60% prevalence of central adrenal insuffi-
ciency (CAI) in children with PWS [25]. Based on the
high prevalence of CAI, the authors suggested treatment
with hydrocortisone during acute illness in patients with
PWS unless CAI has recently been ruled out with a
metyrapone test. ITT, as the gold standard dynamic test
suggests that metyrapone test with an ACTH cut off of
33 pmol/l yields a high false positive rate. In our experi-
ence in the PWS center at Winthrop University Hospi-
tal, New York, we have not found any abnormal
response to ITT or low cortisol levels during surgical
stress of different natures. Three recent studies using a
more sensitive stimulation and spontaneous acute stress
in larger numbers of patients did not find high preva-
lence of central adrenal insufficiency in Prader-Willi
syndrome [26-28]. Thus rather than common, CAI
seems to be a rare event in children and adults with
PWS, however, they should be evaluated and treated
accordingly.
Growth & Growth hormone deficiency
Length in newborns with PWS is normal but there is
significant decrease in growth velocity after age 2-3
years with final adult height ~ 2 standard deviations
(SD) below the mean for the normal population [29-31].
Only a small percentage of children with PWS are GH
sufficient, thus provocative testing is not required in the
face of reduced growth velocity.
Multiple studies have documented the benefits of GH
therapy in individuals with PWS including, but not lim-
ited to, improvements in lean body mass, decreased
body fat, increased bone mineral density, and normaliza-
tion of adult height [19,32-37]. The benefits of starting
GH treatment as early as age 2 years are well estab-
lished, but there is increasing evidence of additional
benefit to starting therapy between ages 6-12 months,
particularly in terms of motor development, muscle,
head circumference, and possibly cognition [35-38].
It should be stressed that GH therapy should be used
in conjunction with appropriate nutritional intake and
physical activity. GH treatment should not be viewed as
a substitute for diet and exercise. Treatment should
commence using standard dose guidelines (0.18-0.3 mg/
kg/week), given as a daily subcutaneous injection with
careful monitoring of clinical status at regular intervals.
Careful history and assessment of nutritional status, sco-
liosis, respiratory and sleep abnormalities should be
evaluated prior to and during GH therapy.
Recent studies indicate that adults with Prader-Willi
syndrome may also benefit from GH replacement ther-
apy, with improvements in body composition, bone
mineral density, exercise capacity, quality of life and
well-being [39-45]. Treatment doses are typically started
at 0.2 mg/day and increased by 0.2 mg increments as
necessary to maintain IGF-1 levels within the normal
range for age and gender. At the present time, docu-
mentation of GH deficiency by provocative testing is
required for adults with PWS to receive insurance
Cataletto et al. International Journal of Pediatric Endocrinology 2011, 2011:12
http://www.ijpeonline.com/content/2011/1/12
Page 4 of 13authorization for GH treatment in the United States.
These patients should be monitored with IGF-1, glucose,
insulin, lipid profile, BMD and cardiac evaluation during
GH treatment [46].
Central hypothyroidism as a result of hypothalamic
dysfunction can also be seen in individuals with PWS.
Periodic monitoring of thyroid function, fasting plasma
glucose and insulin level is strongly recommended
regardless of growth hormone therapy.
Neurocognition and Behavior
Decreased intellectual functioning was among the four
original defining characteristics of PWS [1]. Subsequent
studies document a typical neurobehavioral profile that
includes altered intellectual functioning and centrally
driven maladaptive behaviors, including the hallmark
hyperphagia that exists in the context of a more exten-
sive food related behavioral constellation, an age related
emotional and behavioral profile, altered sensory proces-
sing, social deficits and for many a predictable psychia-
tric profile [47-51].
Intellectual Functioning
Following the original description, early studies of intel-
lectual development documented a wide range of intel-
lectual abilities, although most affected individuals
tested in the borderline to mildly slow IQ ranges. As
more sensitive genetic testing has become available, the
population of individuals with PWS has become more
clearly defined. Table 3 highlights studies of individuals
with PWS who had genetic confirmation of their diag-
nosis, and who received age appropriate and properly
administered cognitive testing, supplemented with mea-
sures of adaptive functioning.
T h eI s r a e l id a t aa r en o t a b l ef o rt h en u m b e ro fi n d i v i -
duals testing in a normal range, and represents a distri-
bution of IQ scores that is quite different from the
remaining four studies. The reasons for this are unclear.
Setting aside the Israeli data and averaging across the
remaining studies, all with approximately the same
number of participants, Full Scale IQ ranges are as fol-
lows: ≥ 70 in 21%; mild cognitive impairment in 47%;
moderate cognitive impairment in 32% and severe to
profound cognitive impairment in 2%. An earlier report
by Curf and Fryns [56] reported a greater proportion of
subjects both in the > 70 and in the mildly impaired
range, however their population included many subjects
for whom no genetic testing was available and thus may
have included individuals who did not have PWS.
Separate from the overall range of functioning among
an affected population is the question of subtype differ-
ences in intellectual functioning. Such differences may
be relevant in understanding the role of various genes in
the overall clinical features and phenotype of this disor-
der. While most studies have not found significant sub-
type differences in overall IQ scores, at least 2 studies
have reported a greater number of UPD subjects with
normal IQ scores when compared to those with deletion
[57-59]. Indeed Torrado et al reported that 61.5% of
those with UPD had a Full scale IQ > 70, while only
10.5% of the subjects with deletion scored in that range.
However, the mean age of Torrado’s subject population
was 4.09 years (range 12 days-17 years), so that the sig-
nificance and overall stability of the obtained IQ scores
is open to question. Statistically significant subtype dif-
ferences have been reported for overall Verbal vs. Per-
formance IQ scores with at least 2 studies reporting that
those with UPD have higher verbal IQ scores and those
with a deletion subtype have higher performance IQ
scores [49,54], although more recently Copet et al [54]
found that only the greater performance IQ of the dele-
tion group vs a disomy group was statistically signifi-
cant. Keep in mind that even when subtype scores are
statistically significant, in no case have those differences
ever reached the level of 1 SD for the test in question.
Thus, whether these statistical differences are reflected
as clinically relevant functional differences between sub-
types is a question that must be raised.
Table 3 Intelligence Quotient (IQ)
Intelligence Quotient
Degree of Mental Retardation (%)
Investigator Year Number enrolled Mean Age* Normal -Borderline Mild Moderate Severe
Einfeld
a [47] 1999 46 17.7 21.6 64.9 13.5 0
Gross-Tsur
b [51] 2001 18 14.3 73 27 0 0
Deschee-Maeker [52] 2002 55 14.1 25.4 27.3 40 7.3
Whittington [53] 2004 55 21.0 31 41.8 27.2 0
Copet [54] 2010 85 24.2 7 54 39 0
Roof [55] 2000 47 23.2 24 38 30 8
a. Only 1/2 of subjects genetically confirmed, most IQ’s from records
b. Did not give a measure of adaptive functioning
*Age in Years
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most individuals with PWS, the overall cognitive profile
at all ages includes cognitive rigidity, attentional deficits,
problems with short term memory, auditory processing,
sequential processing, arithmetic and social cognition.
Relative strengths include long term memory, visual spa-
tial performance, simultaneous processing, unusual abil-
ities with jigsaw puzzles, particularly in the deletion
subtype and for some reading decoding (devoid of
comprehension).
Neuro-behavioral Profile
While there are a number of clinical descriptions of a
typical behavior profile among those with PWS, from
the earliest efforts behavioral studies have primarily
focused on describing and quantifying the development
of problem behaviors and psychiatric difficulties. Despite
calls to include investigations of strength and adaptive
behaviors [60], these remain a rare study focus. More-
over many studies include such a wide age range, often
including infants through late adulthood measured at a
single point in time. Parceling out developmental
aspects of the behavior profile requires a critical combi-
nation of clinical and empirical evidence. Nonetheless
studies across time, taken together, yield a general beha-
vior picture that is remarkably consistent across affected
individuals, despite variation in severity and intensity
across individuals and within the same individual across
time. Foremost among these behaviors is the hyperpha-
gia and associated food related behavior constellation. In
addition, most clinical and empirical studies document
the commonality of hoarding; cognitive rigidity along
with the need for sameness, temper outbursts and emo-
tional lability, repetitive and perseverative behaviors and
skin-picking.
Hyperphagia remains the cardinal defining feature of
PWS. Nonetheless, the hyperphagia is only one aspect
of a larger food-related behavior constellation that
included preoccupations surrounding food; food seek-
ing/foraging; sneaking, hiding and hoarding food; eating
unusual food-related items (sticks of butter, used cook-
ing grease, decaying food, garbage), food flavored items,
such as shampoos and for many, manipulative and
sometimes illegal behaviors designed to acquire food.
While hyperphagia is found in other genetic syndromes
(e.g. WAGR syndrome, Bardet-Biedel syndrome), the
development of the hyperphagia and eating patterns
associated with PWS, distinguish the hyperphagia asso-
ciated with PWS from other disorders. Primary among
these is the relatively late age of emergence, the rapid
escalation and intensification of the hyperphagia follow-
ing several years of poor to relatively normal eating,
often accompanied early on by failure to thrive. Addi-
tional distinguishing characteristics include the duration
of eating, amount of food eaten and a delayed to absent
deceleration of eating, leading to gorging when both
physiologic satiation and volume induced discomfort
should preclude additional intake.
In the daily run of life, this is reflected as constant
talking about food and unrelenting requests and
demands of parents and other caregivers for food, that
when denied often precipitate a tantrum. This frequently
happens at the grocery or while shopping in other stores
that may also have food or candy aisles and at restau-
rants. The denial-related tantrums can be of such a nat-
ure that parents give in as a method of avoiding the
behavior, thus creating a pattern that escalates in sever-
ity and intensity over time. In addition affected indivi-
duals display a constant preoccupation with food
leading to extraordinary vigilance for detecting food
anywhere in the environment often resulting in stealing
other’s lunches at school or work, food from teacher’s
desks or caregiver’s purses, stealing food at home or in
shopping areas, begging others for food, foraging in gar-
bage cans, entering another’s home in search of food
and manipulating others to obtain food. It is a rare par-
ent who has not received a call from the school or voca-
tional site indicating that the affected individual has
been obtaining extra food by convincing caregivers that
parents are ill or haven’t had time to feed them, often
for an extended period of time.
The etiology of the hyperphagia remains elusive. Long
attributed to a hypothalamically mediated failure of sati-
e t yc o n t r o l[ 6 1 , 6 2 ] ,c u r r e n ts t u d i e ss u g g e s taf a rm o r e
complex etiology than previously hypothesized, includ-
ing, for many a theoretical reorientation that views the
hyperphagia as reflecting a starvation syndrome rather
than an obesity syndrome. From this vantage point, the
obesity associated with PWS is seen as resulting from a
physiologic signaling defect indicating that the body is
in a constant state of starvation similar to that of mal-
nourished infants, thus leading to the constant drive to
obtain food.
To date there is no effective pharmacologic interven-
tion. Management is environmental and behavioral,
requiring restricted access to food in all environments,
locks on cabinets and refrigerators, constant supervision,
as well as measures to prevent obesity which include
calorie restrictive diets, consistently scheduled meals
and snacks and regularly scheduled physical activity.
While simple in concept, the number of environments
encountered in any given day, along with the coopera-
tion needed from the individuals in those environments
presents challenges that may be insurmountable for
some families. Accounts from both parents and indivi-
duals with PWS support that strict limit setting with
regard to foraging and food access is associated with
reduced anxiety and a sense of safety [63].
Cataletto et al. International Journal of Pediatric Endocrinology 2011, 2011:12
http://www.ijpeonline.com/content/2011/1/12
Page 6 of 13Behavioral Disturbances
Separate from the food related behavioral issues, multi-
ple studies document that affected individuals are more
prone to behavioral disturbances including hoarding;
inflexibility of thinking and behavior; repetitive and per-
severative behaviors; the need for sameness; tantrums
and emotional lability; and skin picking [62]. Further-
more, the overall rate, severity and chronicity of these
disturbances are frequently more intense than those
associated with comparable genetic disorders or cogni-
tive impairments or other obese groups [43,64,65]. Like
the hyperphagia, the behavioral patterns appear to
evolve over time with predictable epochs. Most authors
agree that, on the whole, infants and young toddlers
with PWS are affectionate, placid and generally cheerful,
largely compliant and usually cooperative. However as
the hyperphagia emerges, a separate and distinctly nega-
tive behavioral shift is also observed including an emer-
gence and escalation of both food and non food related
tantrums, a shorter tolerance for frustration combined
with an overreaction to frustration; repetitive and ritua-
listic behavior as well as becoming “ stuck “ or persever-
ating on issues both in thought and speech; and other
behavior problems including increasing oppositional
tendencies, a lessened ability to “ go with the flow “
along with a drive for sameness and “ increasing stub-
bornness and rigidity “. Comparison studies indicate
that typically developing children and other children
with mental retardation also exhibit the emergence of
such behaviors, but they occur only transiently, that is,
the problem appears and then subsides. However the
emergence of such behaviors in those with PWS not
only is persistent, but appears to escalate with age,
increasing in severity and intensity, independent of intel-
lectual, language or motor abilities [66,67].
Chronic behavior disturbances, including emotional
lability accompanied by unbridled displays of temper;
repetitive, ritualistic and compulsive like behaviors and
hoarding become particularly prevalent in adolescence
and persist well into adulthood, distinguishing these
individuals from both younger children and older indivi-
duals with PWS, as well as from typical adolescents. In
addition there has recently been an increasing recogni-
tion of accompanying social cognition and social inter-
action deficits among affected individuals, including an
inability to read facial expressions of emotion and diffi-
culty interpreting visually presented social information,
such as those inherent in any social interaction [68,69].
Indeed several authors sum up the behavioral profile of
those with PWS as “ egocentric “ and who argue, lie,
manipulate and confabulate to change rules, obtain their
wishes or justify behavior. Their social judgement is
poor, even considering their intellectual ability; and
interpretations of visually presented social information is
on a level with children who have pervasive develop-
mental disorder [62]. Although some behavioral modu-
lation is often seen in later ages, nonetheless
problematic behaviors still exceed those seen in other
comparison groups.
The expression of this behavioral phenotype does
appear to depend, at least to some degree, on genetic
subtype, with hoarding and overt behavioral expressions
of frustration, anger and aggression more common
among those with a deletion, as is a greater likelihood
of modulation in middle adulthood. Internalizing and
autistic spectrum behaviors are more common among
those with UPD, and appear to be unremitting with lit-
tle age related modulation [70,71].
Sensory Issues in the form of an altered sensitivity to
pain, failure to exhibit fevers when expected and high
rates of skin picking and gouging other body areas are
extremely problematic among this group of individuals.
While little research has been done around the issues of
pain and lack of fever when expected, nonetheless
blunted pain sensitivity and lack of appropriate fever
response and the inherent dangers these present are
clinically well documented. In this same spectrum, skin
picking and other similar self injurious behavior occurs
with increased prevalence in PWS when compared to a
general intellectually impaired population [67,72]. When
looking specifically at a population of those with PWS,
skin picking is ubiquitous and when quantified, is as
prevalent and problematic and in some studies even
more so than hyperphagia [47]. It is the source of signif-
icant behavior and medical concerns and management
challenges. Management is directed towards minimizing
both the occurrence and impact of the behavior. To this
end, a recent survey of 67 affected children and adoles-
cents documented skin picking in 96% of respondents,
which were directly associated with measures of anxiety,
inattention, oppositional behaviors, function and quality
of life [73]. Thus separate from medical management,
behavior management must be focused on decreasing
anxiety and boredom while eliminating opportunities for
picking.
A number of case series across time have alluded to a
small subset of individuals for whom seizures were pro-
blematic; however, it was generally thought that these
represented incidental findings rather than a risk asso-
ciated with PWS. A recent report by Fan et al [74]
documented seizure activity in 10 of 56 subjects
between the ages of 1-37 years, with suspicion in yet
another 6 subjects. Among the ten subjects with docu-
mented seizure, one youngster’s seizure disorder was
attributed to sequelae of a grade II intraventricular
hemorrhage associated with an early pre-term birth.
Among the other nine cases, eight occurred in those
with a deletion subtype and the other in a subject
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none were found among those with a disomy. After
reviewing prior studies in which seizures were reported,
the authors conclude that the overall prevalence of sei-
zures in PWS is 16 -17%. Further they suggest that
among those with a deletion, the risk for seizure in a
PWS population is three to four fold times greater than
that expected in a general pediatric population.
Psychiatric Illness
For many, this wide ranging problematic, behavioral
profile can become sufficiently impairing that hospitali-
zation is needed, while for others it evolves into frank
psychiatric difficulties. In fact, Cassidy found behavioral
concerns to be the most frequent cause of hospitaliza-
tion [75]. By late adolescence 15-17% will evidence a
diagnosable mood disorder [76]. This appears to be
especially true for those with UPD. Separate from a
categorical psychiatric diagnosis, studies consistently
document that the level of behavioral and thought psy-
chopathology, such as delusions, paranoid ideation,
common in adolescents and adults with PWS exceeds
that of others with an intellectual disability of other ori-
gins or of a typical population [65,67], and is the pri-
mary source of residential and vocational failure and
family stress among affected adolescents and adults.
While pharmacologic intervention can be helpful and in
the case of psychosis is mandatory, environmental
restructuring and positive behavior support programs
a r ee v e nm o r ec r i t i c a lf o rf a c ilitating recovery and pre-
venting further difficulties.
The proliferation of less invasive and more available
brain imaging techniques during the past decade offers
the possibility of new insights into the central origin of
the behavioral picture associated with PWS. Mantoulan
[77] compared MRI and PET scans in PWS and non-
PWS individuals. MRI images did not show evidence of
anatomic abnormalities. However the PET scans showed
hypoperfused brain regions, particularly in the anterior
cingulum and superior temporal regions. The authors
went on to correlate regional cerebral blood flow (rCBF)
in the hypoperfused regions with results from the Child
Behavior Check list (CBCL) and identified significant
correlations, which suggested that the functional conse-
quences of these perfusion abnormalities in specific
brain regions might help to explain the social and beha-
vioral issues observed in PWS. Similarly, a number of
studies looking at brain processing of food related con-
cerns have yielded mixed findings [78-80]. Functional
findings must be considered tentative as the technology
is sufficiently challenging that few affected individuals
can tolerate the technology nor cooperate with the
necessary tasks. Nonetheless, as the technology evolves,
the possibility for future studies holds great promise.
Sleep Disturbance
General Sleep Disturbances
Sleep disturbance is frequent in all patients with Prader-
Willi syndrome independent of age and weight. PWS
patients with normal weight have been shown to have
multiple sleep disturbances including daytime sleepiness,
disrupted sleep organization, prolonged nocturnal sleep
and sleep disordered breathing (SDB). In infants, SDB
consists primarily of central apneas and absent, reduced
or delayed ventilatory responses and arousal to hypoxia
and hypercapnia [81-84]. Adult individuals with PWS-
related morbid obesity may have the preceding sleep
disturbances as well as an obesity-hypoventilation syn-
drome and obstructive sleep apnea.
Clinical Features
Abnormal sleep-wake organization, daytime sleepiness
and sleep disordered breathing are the most common
sleep related complaints. Irregular REM cycle and sleep
disordered breathing appear as early as during infancy
[85-87].
Sleep wake organization
Early surveys of sleep in PWS reported long nocturnal
sleep (> 8 hours) as a common finding [88]. Early morn-
ing awakenings and sleep fragmentation have also been
reported [89].
T h em o s tc o n s i s t e n tf i n d i n gf o u n di np o l y s o m n o -
graphic studies has been altered rhythm of REM sleep.
S t u d i e sh a v es h o w nat e n d e n c yt o w a r d ss h o r t e rR E M
latency, increased number of REM periods and shorter
intervals between REM cycles. Total percentage of REM
sleep appears to be normal [90-92]. REM sleep altera-
tions appear to be unrelated to the patient genotype
[93].
Excessive daytime sleepiness
Excessive daytime sleepiness (EDS) is an almost univer-
sal characteristic of individuals with PWS [88,89,94].
Clarke et al [88] reported EDS in more than 90% of
their surveyed patients. Those patients who reported
EDS were more likely to exhibit temper tantrums during
the day.
Early studies, using daytime polysomnographic record-
ings, confirmed the presence of pathologic sleepiness in
> 95% of the patients studied [95]. Later studies
employed the multiple sleep latency test (MSLT). This
test, also called a “ nap test “ is used to measure the
time elapsed to sleep onset. It consists of 4 or 5 nap
opportunities during the day. The MSLT is the gold
standard to quantify sleepiness and diagnose disorders
of excessive sleepiness. Studies with MSLT in indivi-
duals with PWS have shown abnormally short sleep
latencies and frequent sleep onset REM periods
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Page 8 of 13(SOREMPs) [90,92,96]. Daytime sleepiness, as measured
by MSLT, appears to be independent of the degree of
sleep related breathing disorders [90,92,96-98], addition-
ally suggesting that daytime sleepiness reflects a central,
possibly hypothalamic hypoarousal.
EDS and the atypical REM sleep findings bear resem-
blance to features of narcolepsy. Indeed, preliminary evi-
dence in a small number of patients showed that
hypocretin deficiency, a characteristic finding in narco-
lepsy, was also found in individuals with PWS who were
severely sleepy [99]. However, in a postmortem study,
there was no significant difference in the number of
hypothalamic hypocretin containing neurons between
patients with PWS and age matched controls [100].
Several preliminary studies have suggested a link
between EDS and disruptive behavior in PWS. Hertz et
al [101] reported a significant correlation between day-
time sleepiness and disruptive behavior as measured by
care taker’s ranking. Similarly, Richdale [89] reported
increased behavioral disturbance in children and adoles-
cents with PWS who also reported EDS. Finally, in
Clarke et al’s [88] survey, adult patients who reported
EDS were more likely to exhibit temper tantrums during
the day.
In contrast, Maas et al [94], reported no significant
correlation between sleep disturbance and behavioral
disturbance in a group of adults with PWS.
Sleep Disordered Breathing (SDB)
Infants with Prader-Willi syndrome, as young as 4
months old, already demonstrate evidence of sleep dis-
ordered breathing. The most frequent type of SDB in
infants with PWS are central apneas and periodic
breathing [85,86]. Hypotonia and central control
abnormalities likely play an important role. As obesity
develops, around age 2 years, sleep apnea of the
obstructive type becomes more common. Obstructive
sleep apnea in both children and adults is directly asso-
ciated with the degree of obesity and is inversely asso-
ciated with age [97]. Oxygen desaturation is commonly
seen even when the Apnea-hypopnea index (AHI) is
only mildly elevated. The degree of sleep related oxygen
desaturation may be severe, especially during REM sleep
related hypotonia. Its severity is significantly increased
with greater body mass index (91).
Management of sleep disorders
A sleep evaluation of all patients with Prader-Willi syn-
drome should be routinely considered because of the
high prevalence of sleep disturbances. Patients who are
habitual snorers and/or sleepy during the day may
require a polysomnogram to rule out sleep disordered
breathing.
In recent years, as more patients are treated with
growth hormone (GH), there has been a growing con-
cern over the potentially adverse effects on sleep related
breathing. GH may exacerbate OSA in PWS, especially
i nt h ep r e s e n c eo fo t h e rr e s p i r atory complications [87].
Review of the death records from the French database
of patients with PWS showed an association with
respiratory tract infections in both GH and non GH
treated patients, highlighting the need for added vigi-
lance during these periods. In patients who were receiv-
ing GH treatment the concern for an adverse outcome
of SDB and respiratory tract infection is particularly sali-
ent during the first nine months of treatment, more so
among males [102]. Therefore, an overnight sleep study
is recommended before GH therapy is instituted to rule
out sleep disordered breathing.
The gold standard for the treatment of sleep apnea in
adults is Continuous Positive Airways Pressure (CPAP)
or BiPAP. In children adenoidectomy, tonsillectomy or
adenotonsillectomy is often first line of treatment. Sup-
plemental oxygen therapy may be added in the presence
of obesity hypoventilation syndrome. The management
of other sleep disturbances may include implementation
of adequate sleep hygiene, sleep wake schedule regula-
tion and even circadian rhythm modification.
In patients who present with excessive daytime sleepi-
ness, a Multiple Sleep Latency Test (MSLT), is also indi-
cated. Once diagnosed, daytime sleepiness can be
managed pharmacologically or with behavioral interven-
tion. The pharmacological management of daytime slee-
piness has been controversial because of the potential
side effects of stimulant medication. Additional research
is needed to assess the effects of stimulant medication on
daytime alertness, disruptive behavior and the general
well being of the sleepy patient with PWS. Behavioral
management of EDS focuses on improving nighttime
sleep and scheduling daytime naps when needed.
Gastrointestinal Issues
Abnormal surges in ghrelin may precede the character-
istic hyperphagia seen in PWS. Whether this causes or
is the result of the lack of satiety in PWS is not clear.
Left unchecked, lack of appetite control can lead to
morbid obesity. Low calorie and well balanced diets
with rigorous supervision and restriction of food access
combined with regularly scheduled meals and activities
are recommended [15]. Reduced energy requirements
have been reported for children with PWS as compared
to healthy, age matched controls [103-105]. Those initi-
ating growth hormone replacement therapy may require
increased caloric load during the initial muscle building
phase, but once lean mass accretion has stabilized, a
reduced caloric limit may again be needed.
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cious eating with a limited time for mastication of food
may lead to choking episodes. Choking accounts for
approximately 8% of all PWS deaths. Binge eating has
been seen in both obese and lean individuals with PWS.
Acute gastric distention with necrosis and death has
been reported with and without binging behavior. While
acute gastric distention is frequently accompanied by
vomiting in the general population, individuals with
PWS have a decreased ability to vomit and may be
missed due to lack of this important finding. These
issues may be further complicated by their increased tol-
erance to pain which may be in part responsible for
delays in seeking medical attention related to these
episodes.
Musculoskeletal Issues
The prevalence of scoliosis in PWS is high (30% before
10 yr of age; 80% after age 10 years) [106-109]. Many
patients shows progression of scoliosis with age irre-
spective of the use of GH and therefore scoliosis should
no longer be considered a contraindication for GH
treatment in children with PWS.
Most published reports of scoliosis in children with
PWS have been retrospective. Recent evaluation of con-
cerns regarding worsening of scoliosis in patients cur-
rently receiving GH have not been substantiated
[110,111]. Prospective studies however are warranted.
Studies by Shim et al [111] showed a high prevalence of
spinal deformity, limb malalignment and foot abnormal-
ities. This group found correlations between various
musculoskeletal abnormalities, independent of obesity,
but noted that obesity may conceal some of these
abnormalities, especially in the early stage. At this time
annual musculoskeletal evaluations are recommended
for scoliosis, hip dysplasia, foot abnormalities and lower
limb malalignments [112].
Slipped femoral capital epiphysis is seen with
increased frequency in otherwise healthy, obese children.
This has not been reported with increased frequency in
children with PWS.
Early work [113] compared gait strategies in patients
with PWS with those of both obese and non obese
healthy patients. Adults with PWS in their study were
found to walk slower, with shorter stride length, lower
cadence and longer stance phases compared to non
PWS controls. Range of motion at the level of the knee
and ankle and plantar-flexor activity were significantly
reduced. Spatio-temporal gait parameters in adults with
PWS were further evaluated. Using 3 D gait analysis in
an attempt to develop rehabilitation therapies, Cimolin
et al [113] found that participating adults with PWS
showed cautious abnormal gait strategies characterized
by longer stance duration, reduced anterior step length
and lower velocity of progression. Hip flexion with a
forward pelvic tilt was present throughout the gait cycle.
Investigators felt that this reflected an attempt to
achieve balance and stability in the face of excessive
body weight.
Prognosis
While there is no cure for Prader-Willi syndrome, major
strides to improve quality of life have been made since
the introduction of more sensitive genetic testing mod-
alities which has allowed early diagnosis and interven-
tion. The early use of GH has improved final adult
height, body composition and muscle strength. Obesity
and the consequences of obesity continue to be major
risk factors for mortality in persons with PWS, even
after correction for the effect associated with intellectual
disability [114].
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